The SARS-CoV-2 coronavirus is the cause of the COVID-19 pandemic. Entry of the virus into host cells, most destructively lung cells, requires two host cell surface proteins, ACE2 and TMPRSS2, downregulation of which is thus a potential therapeutic approach for COVID-19. Both of these cell surface proteins are steroid regulated: TMPRSS2 is a well-characterised androgen-regulated target in prostate cancer. Analysis of sequencing data shows co-expression of the androgen receptor (AR) and TMPRSS2 in key human lung cell types that are targeted by SARS-CoV-2. We show that treatment with antiandrogens such as enzalutamide (a well-tolerated drug widely used in advanced prostate cancer) significantly reduces TMPRSS2 levels in human lung cells and in vivo in mouse lung. We demonstrate that AR binding in the region of the TMPRSS2 gene differs between lung and prostate, identifying distinct regulatory regions. Together, the data and evidence presented supports clinical trials to assess the efficacy of antiandrogens as a treatment option for COVID-19.

**Adipose Tissue, Appetite, and Obesity**

**THE RELATIONSHIP BETWEEN COVID-19 AND ENDOCRINOLOGY**

*Early Follow-up of Atypical Thyroiditis Induced by SARS-CoV-2*

Ilaria Muller, MD, PhD,1 Daniele Cannavaro, MD,2 Davide Dazzi, MD,3 Giovanna Mantovani, MD, PhD,2 Virgilio Longari, MD,4 Marco Cuzzocrea, MD,1 Tiziana E. Re, MD,4 Andrea Gori, MD,1 Maura Arosio, MD, PhD,4 Mario Giovanni Salvi, MD4.

1University of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 2University of Milan, Milan, Italy, 3Ospedale di Vaio, Fidenza, Italy, 4Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.

**Background:** In Spring 2020 the severe acute respiratory syndrome coronavirus 2 pandemic disease (Covid-19) badly affected Northern Italy. We have described for the first time the occurrence of thyrotoxicosis due to atypical subacute thyroiditis in 15% of patients hospitalised for Covid-19 pneumonia, compared with only 1% among patients hospitalised in the same wards during Spring 2019, thus before the Covid-19 pandemic. The whole group of Covid-19 patients also had median serum TSH concentrations significantly lower compared with the control group. The atypical thyroiditis induced by Covid-19 is not associated with neck pain, affects more men than women and especially those severely ill, thus coexists with non-thyroidal illness syndrome. Subacute thyroiditis is classically followed by subacute thyroiditis in 15% of patients hospitalised for Covid-19 due to atypical subacute thyroiditis in 15% of patients hospitalised for Covid-19. This study included patients hospitalized between March 1, 2020 and September 17, 2020 in a hospital health care system in Northeast United States, who had a positive RT-PCR assay of nasopharyngeal swabs for SARS-CoV-2 performed during hospitalization. Body mass index (BMI) was calculated using admission weight and height, and the WHO classification was used to define obesity. Both bivariate and multivariate logistic regression analyses were performed to determine the association of obesity and other clinical factors with outcomes among patients hospitalized for severe coronavirus disease (COVID-19). This study included patients hospitalized between March 1, 2020 and September 17, 2020 in a hospital health care system in Northeast United States, who had a positive RT-PCR assay of nasopharyngeal swabs for SARS-CoV-2 performed during hospitalization. Body mass index (BMI) was calculated using admission weight and height, and the WHO classification was used to define obesity. Both bivariate and multivariate logistic regression analyses were performed to determine the association of obesity and other clinical factors with mortality (defined as in-hospital death or transition to hospice care) and intensive care use (defined by transfer to intensive care unit [ICU]). Multivariate model was adjusted for demographics and 8 pertinent comorbidities. Among 3246 patients hospitalized with COVID-19, median age was 65 years (interquartile range, 51–78), 49.9% were female, 30.5% overweight, and 43.2% had obesity (20.8%,
Adipose Tissue, Appetite, and Obesity
THE RELATIONSHIP BETWEEN COVID-19 AND ENDOCRINOLOGY

Risk of Complications in Children With Type 1 Diabetes and Covid-19
Manish Gope Raisingani, MD.
University of Arkansas for Medical Sciences., LITTLE ROCK, AR, USA.

Background: There is some data available in adults which suggests that Type 1 diabetes may be associated with higher risk with Covid-19 (1). Limited data has been available in pediatric Type 1 diabetes with Covid-19. **Methods:** We used TriNetX, with a large COVID-19 database, collecting real-time electronic medical records data. We compared children (0–18 years) who were diagnosed with Covid-19 with and without Type 1 diabetes. This database collected information from 54 health care organizations. **Results:** Mortality rate in children with Covid-19 and Type 1 diabetes was 0.618% (10/1618). Mortality rate in children with Covid-19 without Type 1 diabetes was 0.195% (32/16618). A total of 542 (16.7%) patients died or received hospice care, and 811 (25.0%) required ICU care. In unadjusted analyses, patients with obesity had lower mortality compared with normal weight adults (13.0% vs. 23.1%) but a higher risk of ICU care (26.5% vs. 22.5%) and longer duration of ICU stays (9.5±10.6 vs. 6.6±8.5 [days]; all p-values <0.05). Obesity was associated with a higher incidence of hypoxic respiratory failure requiring invasive (17.8% vs. 9.3%) and noninvasive (22.7% vs. 14.0%) ventilatory support. In multivariate analysis, older age, male sex, and diabetes were significantly associated with both mortality and ICU care. In contrast, obesity was not associated with a significantly higher mortality (adjusted odds ratio [OR] 1.14; 95% CI, 0.91–1.43) but was associated with a higher risk of ICU care (OR 1.27; 95% CI 1.07–1.51 for all obesity and OR 2.07; 95% CI 1.51–2.82 for class III obesity compared with normal weight). The association of underweight with mortality (OR 1.56; 95% CI 0.93–2.60) and ICU care (OR 1.20; 95% CI, 0.71–1.99) was not statistically significant. This retrospective study of hospitalized patients suggests that obesity is associated with intensive care use and longer duration of ICU stay but not with mortality due to COVID-19. These findings underscore the vulnerability of individuals with obesity during the current pandemic.

Adipose Tissue, Appetite, and Obesity
WHAT'S NEW IN WEIGHT MANAGEMENT THROUGH THE LIFESPAN?

Dextroamphetamine Treatment for Children With Hypothalamic Obesity
Jiska van Schaik, MD, M Sc, Mila Sofie Welling, MD, PhD, Corjan De Groot, MD, PhD, Ozair Abawi, MD, PhD, Murghard M Sc, Lotte Kleindendorst, MD, PhD, Bibian van der Voorn, MD, Mieke M. van Haelst, MD, PhD, Su Bj Oude Ophuis, MD, Gerard Kamp, MD, PhD, Joost Rotteveel, MD, PhD, AYN van Schouten-Meeteren, MD, PhD, Erica LT van den Akker, MD, PhD, and Hanneke Margo van Santen, MD, PhD.

1Wilhelmina Children's Hospital, University Medical Center, Utrecht, Netherlands, 2Erasmus MC Sophia Childrens Hospital, University Medical Center, Rotterdam, Netherlands, 3Vrije Universiteit Amsterdam/University of Amsterdam, Amsterdam, Netherlands, 4Tergooi Hospital, Blaricum, Netherlands, 5Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

**Introduction:** Hypothalamic obesity (HO) in children can be either genetic or acquired, as a result of a suprasellar tumor or its treatment. HO, resulting from hyperphagia and/or a decreased resting energy expenditure (REE), may have devastating consequences for the child and its family. Currently, no effective drug treatment is yet available for HO. Amphetamines – commonly used in children with attention-deficit/hyperactivity disorder – are known for their stimulant effect on REE and inhibitory effect on appetite. We here present our experiences of dextroamphetamine treatment in children and adolescents with acquired or genetic HO. **Methods:** A retrospective cohort evaluation was performed of patients (n = 18) treated with dextroamphetamine at 2 endocrine pediatric clinics. Off-label use of dextroamphetamine was initiated in patients with progressive therapy resistant acquired HO (n = 13) and in patients with genetic obesity (n = 5). Initial treatment dosing was once or twice daily 5mg. This dose was weekly increased with 5 mg/day depending on the patient’s wellbeing and the presence of side effects, to a maximum of 0.5 mg/kg/day. Anthropometrics and REE at start and during follow-up, changes in (hyperphagic) behavior, and side effects were assessed.

**Results:** At start of treatment, mean age was 12.8 years ± 3.4 [range 7.1–17.9] and mean REE was 69.5%± 18.5 (n = 15). At follow-up, mean treatment duration was 18.3 months ± 14.7. Ten out of eighteen children (55.6%) showed clinically relevant weight loss. In 10/13 patients with acquired HO,